key: cord-0863956-xxu7re1m authors: MacMullan, M. A.; Ibrayeva, A.; Trettner, K.; Deming, L.; Das, S.; Tran, F.; Moreno, J. R.; Casian, J. G.; Chellamuthu, P.; Kraft, J.; Kozak, K.; Turner, F. E.; Slepnev, V. I.; Le Page, L. M. title: ELISA detection of SARS-CoV-2 antibodies in saliva date: 2020-08-21 journal: nan DOI: 10.1101/2020.08.17.20176594 sha: 6344bd2b70d633086f63aad9d31c3f57fb8a14eb doc_id: 863956 cord_uid: xxu7re1m To facilitate containment of the COVID-19 pandemic currently active in the United States and across the world, options for easy, non-invasive antibody testing are required. Here we have adapted a commercially available, serum-based ELISA for use with saliva samples, which will enable widespread, affordable testing for patients who experienced this disease. exposure of healthcare personnel during interaction with a patient. As seen with testing for the 27 virus, one sample type has been insufficient and testing per capita has been hugely variable 28 between countries 6 . In the US, the Centers for Disease Control and Protection now recommend 29 options of several upper respiratory tract specimen types 7 from which to test for the virus. This 30 variety of specimen options provides greater opportunity for widespread testing, and the easiest 31 methods of sampling would enable widespread and frequent testing. 32 33 Sensitive antibody tests for other viruses have been successful in dried blood spot 8, 9 and saliva 34 samples [10] [11] [12] . Saliva samples are particularly attractive given the ease and non-invasiveness of 35 sampling, allowing for substantial scaling of testing. Initial discussion 13, 14 and testing in small 36 sample sets indicates the potential for using saliva for SARS-CoV2 antibody testing 15 . 37 In this manuscript we hypothesized that saliva is an acceptable specimen for the detection of 39 SARS-CoV-2 antibodies by standard ELISA. To test this, we first assessed the sensitivity and 40 specificity of two commercially available assays for serum (following manufacturers' instructions). 41 We then investigated multiple strategies for conversion of these assays for antibody detection in 42 saliva using clinical samples collected from RT-PCR-positive participants who were determined 43 to have antibodies as detected by serum testing. 44 45 We conclude that, when following our optimized protocol, it is possible to detect antibodies against 46 SARS-CoV-2 in saliva samples at a sensitivity of 84.2% and a specificity of 100% in the general 47 symptomatic population. If this population is limited to those over the age of 40, sensitivity of 48 91.5% and specificity of 100% is achievable. 49 50 51 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08. 17.20176594 doi: medRxiv preprint Commercially available SARS-CoV-2 serum-based antibody detection ELISA kits from Gold 52 Standard Diagnostics (GSD) and EuroImmun (EI), which detect the nucleocapsid (N) and spike 53 (S) SARS-CoV-2 structural proteins respectively, were evaluated for their efficacy in detecting IgA 54 and IgG antibodies against the novel coronavirus (SARS-CoV-2) in clinical serum samples (Fig. 55 1) . Due to uncertainty about which antibodies are most persistent over time 5 , kits for detecting 56 both IgA and IgG antibodies were evaluated. Kits for detecting IgM antibodies were also 57 considered, but due to a lack of consensus surrounding the persistence of IgM in blood 16 we 58 chose to pursue IgG and IgA antibodies only. 76 serum samples collected prior to November 2019 59 (pre-SARS-CoV-2) were used as a negative control panel to evaluate specificity for both IgG and 60 IgA kits from each manufacturer. We determined that both GSD kits and the EI IgG kit were 100% 61 specific, while the EI IgA kit was 92% specific. We then also tested these kits for sensitivity against 62 clinical serum samples collected between April and July 2020. based on both EI and GSD antibody detection kits, suggesting that these patients were likely 74 infected by COVID-19 prior to their RT-PCR test (Supp. Fig. 1) . 75 76 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint Our objective was to evaluate the ability of these tests to detect antibodies in saliva in addition to 77 detecting antibodies in serum samples. We selected the EI IgG kit for our saliva sample 78 optimization experiments based on its superior performance in our clinical serum sample testing. 79 All clinical study participants provided oral fluid for viral PCR testing and saliva and serum samples 80 for antibody testing. Saliva samples were collected using devices as described in the Methods 81 section. We selected saliva samples from COVID-19 positive participants (as determined by RT-82 PCR) that were also positive for antibodies in serum, and samples from COVID-19 negative 83 participants (as determined by RT-PCR) that were also negative for antibodies in serum. 84 Comparing two different devices in a set of saliva samples (Supp. Fig. 2 ) showed that a 85 mouthwash (inhouse formulation, detailed in Methods section) yielded 100% sensitive and 86 specific results for antibody detection. Increasing our sample size to 50 positive and 33 negative 87 samples reduced the specificity to 93.6% and the sensitivity to 84.0% (AUC = 0.946) ( Fig. 2A) . 88 Based on this data, we further optimized the sample preparation and ELISA processes. 89 First, centrifuging the samples to remove a large pellet of mucin, a common practice among 90 studies of whole saliva samples 12, 17 , gave a sensitivity of 84.0% and specificity of 90.6% (AUC = 91 0.935). Second, the addition of a concentration step (Amicon Ultra Centrifugal Filters) improved 92 sensitivity to 84.4% and specificity to 95.8% (AUC = 0.962). Finally, blocking the ELISA plate with 93 a buffer containing TBS-Tween and 5% BSA for 30 minutes before adding sample yielded an 94 89.2% sensitivity and 96.3% specificity (AUC = 0.965) using a positivity cutoff of 0.40; this final 95 protocol yielded the best sensitivity and specificity for this set of mouthwash samples ( Fig. 2A) . 96 To determine whether the test remained sensitive and specific in an expanded population, we 98 applied this combined protocol (i.e. centrifugation, concentration, and blocking of the ELISA plate) 99 to a larger mouthwash sample group of 82 positive and 67 negative samples. In this population, 100 our test was 84.2% sensitive and 100% specific (AUC = 0.979) using a positivity threshold of 0.56 101 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint (Fig. 2B) . Antibody detection in saliva and serum showed a weak but statistically significant 102 correlation (R=0.596, p<0.0001). (Fig. 2B) . 103 104 Given our cohort of clinical samples (demographics in Fig. 3A) , we wanted to determine if factors 105 linked to COVID-19 susceptibility impacted our sensitivity and specificity. By stratifying the data 106 based on patient demographics of age, sex, and days elapsed since onset of symptoms for 107 sample collection (Supp. Table 1), we found that testing samples only from those over 40 years 108 of age further improved our saliva-based antibody detection test (Fig. 3B) by the FDA guidance (that is, better than 90% sensitivity and 100% specificity). Further work could 118 describe results in asymptomatic COVID-19 positive people, estimated to be as high as 40% of 119 cases 18 . 120 121 Development of this specific, sensitive antibody test from non-invasive samples which require no 122 exposure of healthcare workers to potentially infectious environments may be very valuable. 123 There is currently no documented reinfection in the US, which suggests immunity may be 124 protective on the order of months. Antibody testing could provide significant information for 125 countries interested in establishing the reach of the disease in order to help make policy decisions 126 about reopening towns, cities, and states. 127 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. transported at room temperature before laboratory processing as described 19 . Positive for viral 149 RNA was determined as below 35 cycle threshold (CT). 150 Blood sampling: Participants underwent a standard venipuncture procedure. Briefly, 151 licensed phlebotomists collected a maximum of 15ml whole blood into 3 red-top SST tubes 152 (Becton-Dickinson, cat. number 367988). Once collected, the sample was left at ambient 153 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint temperature for 30-60 minutes to coagulate, then was centrifuged at 2200-2500 rpm for 15 154 minutes at room temperature. Samples were then placed on ice until delivered to the laboratory 155 site where the serum was aliquoted to appropriate volumes for storage at -80 ºC until use. 156 Orasure saliva sample collection: Orasure oral specimen collection devices (catalog 157 number 3001-2870, Orasure, USA) were used as instructed 20 to each kit) and mathematical formula provided by the manufacturer (Equation 2, 3) . 204 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. The data that support the findings of this study are available from the authors upon reasonable 244 request. 245 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 21, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176594 doi: medRxiv preprint Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Timeline of WHO's response to COVID-19 World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard First Case of 2019 Novel Coronavirus in the United States Antibody responses to SARS-CoV-2 in patients with COVID-19 Data. Coronavirus (COVID-19) Testing Interim Guidelines for Clinical Specimens for COVID-19 Enzyme immunoassay for SARS-CoV-2 antibodies in dried blood spot samples: A minimally-invasive approach to facilitate community-and population-based screening Dried blood spots as sample collection method for HCV antibody: a systematic review and meta-analysis Detection of human immunodeficiency virus antibodies in oral fluids Validation of a modified commercial enzyme-linked immunoassay for detection of human immunodeficiency virus type 1 immunoglobulin G antibodies in saliva High similarity of IgG antibody profiles in blood and saliva opens opportunities for saliva based serology Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A General Perspective Saliva-friend and foe in the COVID-19 outbreak COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva Interpreting Diagnostic Tests for SARS-CoV-2 The utility of saliva for the assessment of anti-pneumococcal antibodies: investigation of saliva as a marker of antibody status in serum Prevalence of Asymptomatic SARS-CoV-2 Infection ) 21. OraSure Technologies. Oral Fluid Collection Device Antibody detection tests for COVID-19 (ELISA) Anti-SARS-CoV-2 ELISA (IgG) Instruction for use